US4411903A
Expired / Lapsed
US
⏱️ 0.0 years remaining
4-[(Monosubstituted-alkyl)amino]benzoic acids and analogs as hypolipidemic and antiatherosclerotic agents
Assignee: Wyeth Holdings LLC
•
Filing: 1981-10-22
•
Granted: 1983-10-25
•
Expires: 2001-10-22
Abstract
Abstract This disclosure describes novel 4-](monosubstituted-alkyl)amino]benzoic acids and analogs which are useful as hypolipidemic and antiatherosclerotic agents.
Inventors
- 👤 Robert G. Shepherd
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 22:52
CPC Classifications
C; C07; C07D; C07D213/00; C07D213/02; C07D213/04; C07D213/24; C07D213/28; C07D213/30; C07D207/00; C07D207/02; C07D207/30; C07D207/34; C07D207/42; C07D211/00; C07D211/04; C07D211/06; C07D211/36; C07D211/40; C07D211/44; C07D211/46; C07D213/60; C07D213/62; C07D213/63; C07D213/65; C07D213/78; C07D213/79; C07D213/80; C07D233/00; C07D233/54; C07D233/64; C07D239/00; C07D239/02; C07D239/24; C07D239/28; C07D239/32; C07D239/42; C07D263/00; C07D263/02; C07D263/08; C07D263/10; C07D265/00; C07D265/04; C07D265/06; C07D277/00; C07D277/02; C07D277/04; C07D277/06; C07D303/00; C07D303/02; C07D303/12; C07D303/16; C07D307/00; C07D307/02; C07D307/34; C07D307/38; C07D307/54; C07D307/56; C07D307/66; C07D307/68; C07D307/70; C07D307/71; C07D309/00; C07D309/02; C07D309/08; C07D309/10; C07D309/12; C07D317/00; C07D317/08; C07D317/10; C07D317/14; C07D317/28; C07D333/00; C07D333/02; C07D333/04; C07D333/06; C07D333/14; C07D333/16; C07D333/20; C07D333/22; C07D333/24; C07D333/26; C07D333/30; C07D333/36; C07D333/38; C07D333/42; C07D333/44
Claims Analysis
Total Claims: 15
Claim 1
Independent Claim
96 words
The method of inhibiting atherosclerotic lesion development in a mammal comprising the administration of an effective lesion-development inhibiting amount of a compound of the formula: ##STR2## wherein X is selected from the group consisting of chloro, bromo, and iodo; A is an unbranched or branched saturated alkylene group, represented by the formula C n H 2n with n being an integer from 7 to 18 inclusive; R 1 is hydrogen; and Z represents the atoms necessary to complete a pyrrolidino or piperidino radical; and the pharmaceutically acceptable non-toxic acid-addition and cationic salts thereof to said mammal.
Claim 2
Independent Claim
96 words
The method of inhibiting atherosclerotic lesion development in a mammal comprising the administration of an effective lesion-development inhibiting amount of a compound of the formula: ##STR2## wherein X is selected from the group consisting of chloro, bromo, and iodo; A is an unbranched or branched saturated alkylene group, represented by the formula C n H 2n with n being an integer from 7 to 18 inclusive; R 1 is hydrogen; and Z represents the atoms necessary to complete a pyrrolidino or piperidino radical; and the pharmaceutically acceptable non-toxic acid-addition and cationic salts thereof to said mammal.
Claim 3
Dependent Claim
28 words
The method of inhibiting atherosclerotic lesion development in a mammal comprising the administration of an effective lesion-development inhibiting amount of a compound of claim 1 to said mammal.
Claim 4
Dependent Claim
32 words
The method of claim 1, wherein said compound is administered to provide a daily dosage of from about one mg. to about 250 mg. per kilogram of body weight of said mammal.
Claim 5
Dependent Claim
32 words
The method of claim 2, wherein said compound is administered to provide a daily dosage of from about one mg. to about 250 mg. per kilogram of body weight of said mammal.
Claim 6
Dependent Claim
40 words
An antiatherosclerotic composition in dosage-unit form useful for preventing or diminishing atherosclerotic lesion formation in mammals comprising from about one mg to about 250 mg. per kilogram of body weight per daily dosage unit of a compound of claim 1.
Claim 7
Dependent Claim
40 words
An antiatherosclerotic composition in dosage-unit form useful for preventing or diminishing atherosclerotic lesion formation in mammals comprising from about one mg to about 250 mg. per kilogram of body weight per daily dosage unit of a compound of claim 1.
Claim 8
Dependent Claim
27 words
The method of inducing regression of atherosclerotic lesion development in a mammal comprising administering to said mammal an effective lesion-regressive amount of a compound of claim 1.
Claim 9
Dependent Claim
27 words
The method of inducing regression of atherosclerotic lesion development in a mammal comprising administering to said mammal an effective lesion-regressive amount of a compound of claim 1.
Claim 10
Dependent Claim
32 words
The method of claim 7, wherein said compound is administered to provide a daily dosage of from about one mg. to about 250 mg. per kilogram of body weight of said mammal.
Claim 11
Dependent Claim
32 words
The method of claim 8, wherein said compound is administered to provide a daily dosage of from about one mg. to about 250 mg. per kilogram of body weight of said mammal.
Claim 12
Dependent Claim
41 words
The method of treating hyperlipidemia and hyperlipoproteinemia and/or altering the lipoprotein pattern in a mammal comprising administration to said mammal of an effective lipid-altering amount of a compound selected from the group consisting of those of the formula of claim 1.
Claim 13
Dependent Claim
41 words
The method of treating hyperlipidemia and hyperlipoproteinemia and/or altering the lipoprotein pattern in a mammal comprising administration to said mammal of an effective lipid-altering amount of a compound selected from the group consisting of those of the formula of claim 1.
Claim 14
Dependent Claim
11 words
A method according to claim 1 wherein the compound is 1-[4-(16-bromohexadecylamino)benzoyl]piperidine.
Claim 15
Dependent Claim
11 words
A method according to claim 1 wherein the compound is 1-[4-(16-bromohexadecylamino)benzoyl]pyrrolidine.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1986-10-24 | 1987-04-25 | 1987-10-25 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1990-10-24 | 1991-04-25 | 1991-10-25 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1994-10-24 | 1995-04-25 | 1995-10-25 | $7700.00 | Window Closed / Lapsed |